Diquafosol for Soft Contact Lens Dryness: Clinical Evaluation and Tear Analysis.
To evaluate the efficacy of topical application of 3% diquafosol tetrasodium solution for the treatment of soft contact lens (SCL) wearers with dryness. In addition to clinical tests and subjective symptoms, we assessed the fluorescence intensity of wheat germ agglutinin conjugate of fluorescein (F-WGA) used as a marker of membrane-associated mucins and sialic acid concentration in tear fluids as a marker of secreted mucins.



Twelve SCL wearers with dryness symptoms were treated with diquafosol for 4 weeks. Clinical tests included the tear film break-up time (BUT), corneal and conjunctival fluorescein staining scores, and Schirmer values. Subjective symptoms were evaluated by the Dry Eye-Related Quality-of-Life Score (DEQS). Fluorescence intensities in the central cornea were measured by fluorophotometry at 5 minutes after a 5% F-WGA solution was applied to the eye. The tears collected by the Schirmer test strips were analyzed by high-performance liquid chromatography (HPLC), and the concentrations of sialic acid; total protein; and the four major tear proteins secretory IgA, lactoferrin, lipocalin-1, and lysozyme proteins were measured.



Comparing the results before and after diquafosol treatment, BUT (p < 0.01), kerato-conjunctival staining score (p < 0.05), corneal staining score (p < 0.05), and DEQS score (p < 0.01) showed statistically significant improvements. The F-WGA fluorescence intensities (p < 0.0001) significantly increased after treatment, whereas the concentrations of sialic acid and tear proteins remained unchanged.



Topical application of diquafosol solution to the SCL wearers with dryness improved biomarker of membrane-associated mucins, BUT, staining of cornea and conjunctiva, and subjective symptoms.
*MD †MD, PhD ‡MS Department of Ophthalmology, Kyorin University School of Medicine, Tokyo, Japan (CS, MY); and Division for Vision Research, National Institute of Sensory Organs, National Hospital Organization Tokyo Medical Center, Tokyo, Japan (CS, MY, YA, MF).
Chika
C
Shigeyasu
Masakazu
M
Yamada
Yoko
Y
Akune
Masaki
M
Fukui
D000328:Adult; D002851:Chromatography, High Pressure Liquid; D003263:Contact Lenses, Hydrophilic / Q000009:adverse effects*; D003315:Cornea / Q000473:pathology*; D015352:Dry Eye Syndromes / Q000175:diagnosis / Q000209:etiology / Q000517:prevention & control*; D005136:Eye Proteins / Q000032:analysis*; D005260:Female; D015590:Fluorophotometry; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009883:Ophthalmic Solutions; D011122:Polyphosphates / Q000494:pharmacology*; D011446:Prospective Studies; D013666:Tears / Q000737:chemistry*; D014500:Uracil Nucleotides / Q000494:pharmacology*; D055815:Young Adult
D005136:Eye Proteins; D009883:Ophthalmic Solutions; D011122:Polyphosphates; D014500:Uracil Nucleotides; C042434:tear proteins; C403315:diquafosol